Table 2.
Comparison of liver function at baseline and 3 months posttreatment.
| Baseline | 3-month value | P | |
|---|---|---|---|
| TB (mg/dl) | TB (mg/dl) | ||
| ISP-TACE group | 1.2 (0.9–2.0) | 1.3 (0.9–1.7) | 0.99 |
| Sora-TACE group | 1.2 (0.8–1.9) | 1.5 (1.3–2.0) | 0.07 |
| Albumin (g/l) | Albumin (g/l) | ||
| ISP-TACE group | 37.6 (32.0–42.3) | 36.0 (30.9–38.8) | 0.25 |
| Sora-TACE group | 36.8 (32.8–40.2) | 35.5 (31.5–37.8) | 0.03 |
| AST (U/l) | AST (U/l) | ||
| ISP-TACE group | 59.2 (50.6–67.8) | 40.4 (34.5–47.1) | <0.001 |
| Sora-TACE group | 60.0 (43.6–94.5) | 72.5 (63.5–82.2) | <0.001 |
| ALT (U/l) | ALT (U/l) | ||
| ISP-TACE group | 45.1(38.5–51.7) | 33.3(28.1–38.3) | <0.001 |
| Sora-TACE group | 39.6(34.4–44.8) | 46.2(40.1–52.3) | <0.001 |
ALT, alanine transaminase; AST, aspartate transaminase; ISP-TACE, irradiation stent placement plus transcatheter arterial chemoembolization; Sora-TACE, sorafenib plus transcatheter arterial chemoembolization; TB, total bilirubin.